X-Biotix discovers and develops first-in-class small-molecule antibiotic compounds against multidrug-resistant Gram-negative pathogens using a DNA-encoded library platform. The company is advancing multiple programs identified against essential bacterial pathways predicted to avoid known resistance mechanisms. It has demonstrated in vivo efficacy for its lead programs and has continued preclinical development. X-Biotix closed an extension to its Series A financing to support further preclinical work and pipeline advancement. The company was incorporated in 2016, is based in Waltham, MA, and its co-founders include faculty from Harvard Medical School. X-Biotix joined the Antimicrobials Working Group in July 2019 and recently added industry veteran Mike Bonney to its advisory team to support development and commercialization planning. X-Biotix Therapeutics is a discovery, early preclinical-stage company focused on discovering and developing novel small-molecule antibiotic scaffolds targeting multi-drug-resistant Gram-negative pathogens. It was spun out of X-Chem and leverages X-Chem's DEXTM DNA-encoded library platform, in collaboration with senior investigators at Harvard Medical School and under a technology license from Harvard University, to identify scaffolds active against essential Gram-negative pathways. The company was incorporated in 2016 and is located in Waltham, MA. Proceeds from the recently secured $7 million Series A will enable X-Biotix to advance its pipeline of antibiotic candidates against a wide range of biological targets. Leadership additions accompanying the financing include Stephen T. Isaacs as chairman, Christopher Ray as a director, and Dominic Ryan, Ph.D., as chief scientific officer to strengthen drug discovery and development capabilities. X-Biotix pursues a multi-target discovery strategy to rapidly identify and validate novel small-molecule scaffolds predicted to defeat known resistance mechanisms and address indications such as bacteremia, hospital- and ventilator-acquired pneumonia, and other complicated nosocomial infections.

Total raised

$7M

Funding rounds

2

Latest round

Series A

Latest activity

Apr 2018